Loading
A phase 1/2 trial of AT101 in hodgkin lymphoma and non-hodgkin lymphoma, run by AbClon, now recruiting.
Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma is a phase 1/2 interventional study registered as NCT05338931 by AbClon, with 82 participants planned, started 2022-03-15 and due to reach its primary completion in 2030-03-15. Interventions recorded: AT101(Anti-CD19 Chimeric Antigen Receptor T cell). Conditions listed: B-cell Non Hodgkin Lymphoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/